Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05547906 Completed - Solid Tumor Clinical Trials

Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

Start date: November 8, 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.

NCT ID: NCT05547321 Recruiting - Clinical trials for Advanced Solid Tumor

Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.

Start date: October 20, 2022
Phase: Phase 1
Study type: Interventional

Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.

NCT ID: NCT05544929 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Start date: October 26, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

NCT ID: NCT05544552 Recruiting - Bladder Cancer Clinical Trials

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

SURF301
Start date: November 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.

NCT ID: NCT05544019 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study of SGR-1505 in Mature B-Cell Neoplasms

Start date: April 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

NCT ID: NCT05541822 Recruiting - Clinical trials for Advanced Solid Tumors

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

Start date: January 17, 2023
Phase: Phase 2
Study type: Interventional

ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 in specific populations of advance solid tumors with c-MET alterations as monotherapy.

NCT ID: NCT05539833 Recruiting - Clinical trials for Refractory Solid Tumors

KSH01-TCRT Solid Tumors

KSH01-TCRT
Start date: August 19, 2022
Phase: Early Phase 1
Study type: Interventional

1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

NCT ID: NCT05539768 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor

Start date: October 8, 2022
Phase: Early Phase 1
Study type: Interventional

Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.

NCT ID: NCT05539677 Recruiting - Prostate Cancer Clinical Trials

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

REGATA
Start date: September 1998
Phase:
Study type: Observational [Patient Registry]

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies

NCT ID: NCT05539157 Active, not recruiting - Clinical trials for Malignant Solid Tumor

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Start date: October 18, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors